In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023
The potent in vitro activity of sulopenem against this large collection of contemporary Enterobacterales clinical isolates from multiple infection types supports its use in the treatment of uncomplicated UTI, as well as its further clinical evaluation in the treatment of other common bacterial infections demonstrating resistant phenotypes.
Authors
- Kelley A. Fedler (ORCID: https://orcid.org/0000-0001-8717-2259)
- Michael W. Dunne (ORCID: https://orcid.org/0000-0001-6186-5196)
- Steven I. Aronin (ORCID: https://orcid.org/0000-0002-4041-043X)
- Michael D. Huband (ORCID: https://orcid.org/0000-0002-9769-9019)
- H. D. Becker
Institutions
- Saybrook University (US)
- Fulcrum Therapeutics (United States) (US)
- JMI Laboratories (US)
- Optimum Therapeutics (United States) (US)
- Element Six (United States) (US)
Publication Details
- Journal
- Journal of Global Antimicrobial Resistance
- Published
- 2025-06-22
- DOI
- https://doi.org/10.1016/j.jgar.2025.06.013
- Citations
- 2
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 2.79